About Lactobacillus rhamnosus
Genus renamed from Lactobacillus to Lacticaseibacillus in 2020; covers non-GG L. rhamnosus strains (the well-studied GG/ATCC 53103 strain has its own entry). HN001 has RCTs for reduced eczema/atopy risk in infants; GR-1 has RCTs (with L. reuteri) for urogenital/vaginal health. Strain-specific: benefits do not transfer across strains. Most appearances here are presence-only in multi-strain blends.
What Lactobacillus rhamnosus supports
- Some strains show moderate clinical evidence for gut and immune support
- HN001 studied for reduced eczema risk in at-risk infants
How much Lactobacillus rhamnosus to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1–20
billion_cfu
No single established therapeutic dose across strains; RCTs of L. rhamnosus strains typically use 1-20 billion CFU/day. Usually a presence-only blend component; nominal range.
Clinical evidence
Moderate clinical evidence. Moderate: strain-specific RCTs (HN001, GR-1) but not a whole-species claim.
Examine.com